Developer docs
API playgroundTry for free, no card

Search company profiles

Amaranth Medical

Full company profile

uuid000a2zl

Namestring
Amaranth Medical
Websiteurl
amaranthmedical.com
Company typeenum
Private
Founded yearint
2005
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
bioresorbable scaffolds, vascular implant devices, cardiovascular stents, medical device manufacturing, bioresorbable polymers
Industry1 code
1Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
CodeHLAAAGABPrimaryYes
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Bioresorbable Vascular Scaffolds / Cardiovascular Medical Devices
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Amaranth Medical develops and manufactures fully bioresorbable, versatile scaffolds with novel mechanical properties for medical use. The company's core products are bioresorbable vascular scaffolds (BVS) designed to provide temporary mechanical support to vessels and then resorb into the body, targeting the cardiovascular interventional device market.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Fully Bioresorbable Vascular Scaffold (BVS) Platform
CategoryCardiovascular Medical Devices / Bioresorbable Scaffolds
Description

A fully bioresorbable, versatile scaffold with novel mechanical properties designed to provide temporary mechanical support to vessels and then resorb into the body. It is intended for use by interventional cardiologists and hospitals performing vascular intervention procedures as an alternative to permanent metallic stents.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers8 records
1Boston Scientific
TypeBroad incumbent
Description

Leading interventional cardiology incumbent with bioresorbable scaffold R&D programs and a broad portfolio of drug-eluting stents; a logical strategic acquirer or partner for an early-stage scaffold developer.

2Elixir Medical
TypeDirect peer
Description

Develops bioresorbable scaffold systems (e.g., DESolve, DynamX) for coronary artery disease; competes in the same product category and faces the same regulatory and clinical-trial hurdles as Amaranth.

3Arterius Limited
TypeEmerging player
Description

UK-based developer of bioresorbable scaffolds using a unique PLLA-based technology platform; comparable as a small emerging player in the same scaffold category.

4Meril Life Sciences
TypeDirect peer
Description

India-based developer of the MeRes100 bioresorbable vascular scaffold with CE Mark approval; represents the most clinically advanced direct competitor in the same product niche.

5Sahajanand Medical Technologies
TypeRegional player
Description

Indian manufacturer of cardiovascular implants including bioresorbable scaffolds; comparable as a regional scaffold developer with overlapping technology focus.

6Abbott Laboratories
TypeBroad incumbent
Description

Developed and commercialized the Absorb GT1 bioresorbable vascular scaffold before withdrawing it from global markets in 2017; remains the most directly comparable large incumbent with deep cardiac device infrastructure and potential interest in re-entering the category.

7REVA Medical
TypeDirect peer
Description

Pure-play bioresorbable scaffold developer (Fantom and Tyrocore platforms) targeting peripheral and coronary applications — the closest direct comparable to Amaranth's tissue-engineered scaffold approach.

8Transluminal Technologies
TypeEmerging player
Description

Small US-based developer focused on bioresorbable polymer technologies for cardiovascular applications; comparable as a similarly sized emerging scaffold platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amaranth Medical

Bioresorbable Vascular Scaffolds / Cardiovascular Medical Devicesamaranthmedical.com

Amaranth Medical firmographics

Firmographics
Name
Amaranth Medical
Website
https://amaranthmedical.com
Company type
Private
Founded year
2005
Headcount range
11–50 employees
Ownership category
akta.pro rank

Amaranth Medical industry classification

Industry
Product category
Bioresorbable Vascular Scaffolds / Cardiovascular Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

  • Bioresorbable scaffolds
  • Vascular implant devices
  • Cardiovascular stents
  • Medical device manufacturing
  • Bioresorbable polymers

Where Amaranth Medical is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Markets served

Amaranth Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Amaranth Medical product offering

Product offering

Core offering

Amaranth Medical develops and manufactures fully bioresorbable, versatile scaffolds with novel mechanical properties for medical use. The company's core products are bioresorbable vascular scaffolds (BVS) designed to provide temporary mechanical support to vessels and then resorb into the body, targeting the cardiovascular interventional device market.

Differentiator

Problem solved

Functional benefit

Products and services

  • Fully Bioresorbable Vascular Scaffold (BVS) Platform A fully bioresorbable, versatile scaffold with novel mechanical properties designed to provide temporary mechanical support to vessels and then resorb into the body. It is intended for use by interventional cardiologists and hospitals performing vascular intervention procedures as an alternative to permanent metallic stents.

Companies that use Amaranth Medical

Customer profile

Ideal customer profiles1 record

Amaranth Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Amaranth Medical partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights1 record

Amaranth Medical competitors and assessment

Company assessment

Broad incumbents

  • Boston Scientific: Leading interventional cardiology incumbent with bioresorbable scaffold R&D programs and a broad portfolio of drug-eluting stents; a logical strategic acquirer or partner for an early-stage scaffold developer.
  • Abbott Laboratories: Developed and commercialized the Absorb GT1 bioresorbable vascular scaffold before withdrawing it from global markets in 2017; remains the most directly comparable large incumbent with deep cardiac device infrastructure and potential interest in re-entering the category.

Direct peers

  • Elixir Medical: Develops bioresorbable scaffold systems (e.g., DESolve, DynamX) for coronary artery disease; competes in the same product category and faces the same regulatory and clinical-trial hurdles as Amaranth.
  • Meril Life Sciences: India-based developer of the MeRes100 bioresorbable vascular scaffold with CE Mark approval; represents the most clinically advanced direct competitor in the same product niche.
  • REVA Medical: Pure-play bioresorbable scaffold developer (Fantom and Tyrocore platforms) targeting peripheral and coronary applications — the closest direct comparable to Amaranth's tissue-engineered scaffold approach.

Emerging players

  • Arterius Limited: UK-based developer of bioresorbable scaffolds using a unique PLLA-based technology platform; comparable as a small emerging player in the same scaffold category.
  • Transluminal Technologies: Small US-based developer focused on bioresorbable polymer technologies for cardiovascular applications; comparable as a similarly sized emerging scaffold platform.

Regional players

  • Sahajanand Medical Technologies: Indian manufacturer of cardiovascular implants including bioresorbable scaffolds; comparable as a regional scaffold developer with overlapping technology focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Amaranth Medical social profiles

Digital presence

Amaranth Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amaranth Medical leadership team

Management profile

Number of profiles

Profiles2 records

Amaranth Medical funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amaranth Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amaranth Medical

What does Amaranth Medical do?

Amaranth Medical develops and manufactures fully bioresorbable, versatile scaffolds with novel mechanical properties for medical use. The company's core products are bioresorbable vascular scaffolds (BVS) designed to provide temporary mechanical support to vessels and then resorb into the body, targeting the cardiovascular interventional device market.

When was Amaranth Medical founded?

Amaranth Medical was founded in 2005. It employs 11 to 50 people.

Where is Amaranth Medical based?

Amaranth Medical is headquartered in Mountain View, United States, in the North America region.

Who are Amaranth Medical's main competitors?

Broad incumbents on record are Boston Scientific and Abbott Laboratories. Direct peers are Elixir Medical, Meril Life Sciences and REVA Medical. Emerging players are Arterius Limited and Transluminal Technologies. Sahajanand Medical Technologies is listed as a regional player.

Does Amaranth Medical have an API?

No public API is recorded for Amaranth Medical.

What industry is Amaranth Medical in?

Amaranth Medical's product category is Bioresorbable Vascular Scaffolds / Cardiovascular Medical Devices. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAmaranth Presented MAGNITUDE (98 micron) Nine-Month Follow-up Clinical Results and Introduced DEFIANCE (85 micron) BRS Development Plan at TCTAmaranth Medical presented nine-month follow-up results of its 98-micron MAGNITUDE scaffold at TCT, showing low MACE (2.9%) and binary restenosis (4.5%). The company also introduced its 85-micron DEFIANCE scaffold development plan, with CE Mark targets for APTITUDE and MAGNITUDE.GlobeNewswireAmaranth Presented Interim Nine-Month Follow-up MAGNITUDE (98 micron) and Two-Year Follow-up APTITUDE (115 micron) Data at EuroPCR SymposiumAmaranth Medical presented interim nine-month follow-up data for its 98-micron MAGNITUDE scaffold and two-year data for its 115-micron APTITUDE scaffold at EuroPCR 2018. MAGNITUDE showed 97.3% device success and 7.9% binary restenosis, while APTITUDE had 98.3% success and no restenosis or thrombosis. The company also highlighted its 85-micron DEFIANCE scaffold, expected to enter clinical studies in 2019.GlobeNewswireAmaranth Medical Showcases Breadth of BRS Pipeline at TCT, Unveiling 9-mo Interim Imaging Results from 98 micron MAGNITUDE and Update on 115-micron APTITUDEAmaranth Medical will present its bioresorbable scaffold pipeline at TCT, including 9-month imaging results from 12 of 70 patients in the RENASCENT-III study of 98-micron MAGNITUDE. The company also reported 9-month follow-up from the 60-patient RENASCENT-II study of 115-micron APTITUDE, with CE Mark applications submitted for both products.PR NewswireGlobal Bioresorbable Scaffolds IndustryThis industry report analyzes the global bioresorbable scaffolds/stents market from 2016 through 2024, covering US, Europe, Asia-Pacific, and Rest of World segments. Abbott Laboratories halted global sales of its Absorb bioresorbable stent citing adverse events, significantly impacting the industry, while competitors including BIOTRONIK, Elixir Medical, and Amaranth Medical continued advancing their own products through clinical trials and regulatory approvals. The report profiles 17 companies and identifies developing countries as key growth opportunities driven by rising cardiovascular disease prevalence and healthcare expenditure.GlobeNewswireAmaranth Medical Completes Enrollment in RENASCENT-II Study of 120-Micron APTITUDE™ Sirolimus-Eluting Bioresorbable ScaffoldAmaranth Medical completed enrollment in May 2016 in the RENASCENT-II study of its 120-micron APTITUDE scaffold, with no major peri-procedural complications. Interim results are expected at TCT this fall, and the company plans to use data for a CE Mark application. It also announced initiation of RENASCENT-III in Q4 2016.GlobeNewswireAmaranth Medical On Track to Complete Enrollment inAmaranth Medical's RENASCENT-II study of its APTITUDE scaffold is about to complete enrollment, with interim results expected at TCT this fall. The company plans to apply for CE Mark approval this year and commercialize APTITUDE in 2017, pending positive follow-up results.GlobeNewswireAmaranth Medical Completes MEND-II and RENASCENT Studies and Initiates Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable ScaffoldAmaranth Medical completed enrollment in MEND-II and RENASCENT-I trials of its FORTITUDE sirolimus-eluting bioresorbable scaffold, with all patients entering a nine-month follow-up period. The company announced initiation of RENASCENT-II, a study of a 120-micron scaffold, and plans to apply for CE Mark after follow-up concludes, potentially commercializing in 2017.GlobeNewswireAmaranth Medical Initiates Clinical Trial of the Second-Generation FORTITUDE Bioresorbable Drug-Eluting ScaffoldAmaranth Medical began patient enrollment in Colombia for MEND-II, a trial of its FORTITUDE sirolimus-eluting bioresorbable scaffold. The company also presented MEND-I results, which met its primary endpoint with no stent thrombosis or mechanical failure. A European study is planned for next year to support a CE Mark application.DAICBoston Scientific Invests in Bioresorbable Stent Startup Amaranth MedicalAmaranth Medical said on January 14, 2014 that Boston Scientific Corp. closed an equity investment, with proceeds funding clinical development of the Amaranth Fortitude drug-eluting bioresorbable scaffold in a planned international study and CE marking. The company previously evaluated the non-drug-eluting version in 13 patients, showing maintained mechanical integrity. A second patient cohort will enroll in 2014.GlobeNewswireAmaranth Medical Announces Investment from Boston ScientificAmaranth Medical closed an equity investment from Boston Scientific to advance clinical development of its FORTITUDE bioresorbable scaffold. The funding will support a planned international clinical study and CE Mark application, with a second cohort of patients to be enrolled in 2014.